Canada markets closed

Santen Pharmaceutical Co., Ltd. (SNPHY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
9.99+0.04 (+0.38%)
At close: 11:02AM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 3.63B
Enterprise Value 3.08B
Trailing P/E 20.86
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)1.91
Price/Book (mrq)1.89
Enterprise Value/Revenue 0.01
Enterprise Value/EBITDA 0.05

Trading Information

Stock Price History

Beta (5Y Monthly) 0.26
52-Week Change 316.65%
S&P500 52-Week Change 322.38%
52 Week High 310.80
52 Week Low 38.08
50-Day Moving Average 39.70
200-Day Moving Average 39.42

Share Statistics

Avg Vol (3 month) 35.96k
Avg Vol (10 day) 31.04k
Shares Outstanding 5363.26M
Implied Shares Outstanding 6364.77M
Float 8349.13M
% Held by Insiders 10.00%
% Held by Institutions 10.02%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 40.22
Forward Annual Dividend Yield 42.18%
Trailing Annual Dividend Rate 332.00
Trailing Annual Dividend Yield 3321.53%
5 Year Average Dividend Yield 42.13
Payout Ratio 441.31%
Dividend Date 3Jul 11, 2019
Ex-Dividend Date 4Sept 28, 2023
Last Split Factor 22499:1000
Last Split Date 3Apr 02, 2015

Financial Highlights

Currency in JPY.

Fiscal Year

Fiscal Year Ends Mar 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 9.18%
Operating Margin (ttm)14.36%

Management Effectiveness

Return on Assets (ttm)12.03%
Return on Equity (ttm)9.26%

Income Statement

Revenue (ttm)302.08B
Revenue Per Share (ttm)815.26
Quarterly Revenue Growth (yoy)8.70%
Gross Profit (ttm)N/A
EBITDA 99.33B
Net Income Avi to Common (ttm)27.71B
Diluted EPS (ttm)0.48
Quarterly Earnings Growth (yoy)22.70%

Balance Sheet

Total Cash (mrq)83.36B
Total Cash Per Share (mrq)229.51
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)2.46
Book Value Per Share (mrq)822.49

Cash Flow Statement

Operating Cash Flow (ttm)68.11B
Levered Free Cash Flow (ttm)76.02B